CoChat

Ursodiol for the Long-Term Treatment of Primary Biliary Cirrhosis

Poupon, Renee E., Poupon, Raoul, Balkau, Beverley · 1994 · New England Journal of Medicine

The DOI matches its Crossref record, with a small difference in title or year; 36 of the 36 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Ursodiol (ursodeoxycholic acid) therapy leads to major improvements in patients with primary biliary cirrhosis. The benefit of long-term treatment is uncertain. METHODS: We randomly assigned 145 patients with biopsy-proved primary biliary cirrhosis to receive ursodiol (13 to 15 mg per kilogram of body weight per day) (72 patients) or placebo (73 patients). After two years of follow-up, because of the benefit from ursodiol, all patients completing the study received ursodiol in an open trial and were monitored for two more years. The end points in the assessment of efficacy were as follows: progression of disease, as defined by the presence of hyperbilirubinemia, variceal bleeding, ascites, or encephalopathy; liver transplantation or a referral for that procedure; and liver transplantation (or a referral) or death. RESULTS: Disease progressed significantly less frequently in the ursodiol group than in the placebo group (P < 0.002; relative risk, 0.28; 95 percent confidence interval, 0.12 to 0.63). The probability of liver transplantation or a referral for that procedure and the probability of transplantation or death were significantly lower in the group assigned to ursodiol than in the group assigned to placebo (for transplantation alone, P = 0.003; relative risk, 0.21; 95 percent confidence interval, 0.07 to 0.66; for transplantation or death, P = 0.005; relative risk, 0.32; 95 percent confidence interval, 0.14 to 0.74). High bilirubin levels and, to a lesser extent, signs of cirrhosis at entry into the trial were predictive of disease progression, liver transplantation or a referral, and transplantation or death. CONCLUSIONS: Long-term ursodiol therapy slows the progression of primary biliary cirrhosis and reduces the need for liver transplantation.

Overview

Integrity signals

Registry

Crossref · 10.1056/nejm199405123301903

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Show all 36 references

Research works printed but not linked: 5

  1. Triger DR, 1980, Gut, 21, A919
  2. Bassendine MF, 1982, Gut, 23, A909
  3. Lindor KD, 1992, Hepatology, 16, 91A
  4. Heathcote EJL, 1992, Hepatology, 16, 91A
  5. Goudie BM, 1989, Am J Gastroenterol, 84, 713

Cited by

See all 497

Metadata

Authors
Poupon, R. E., Poupon, R., & Balkau, B.
Affiliations
Inserm (FR)
Venue
New England Journal of Medicine
Published
1994-05-12
Volume
330
Issue
19
Pages
1342-1347
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2324587274
Cited by
497
References
35
Citations by year
2026: 10 · 2025: 12 · 2024: 18 · 2023: 6 · 2022: 8 · 2021: 10 · 2020: 12 · 2019: 19 · 2018: 18 · 2017: 14 · 2016: 12 · 2015: 16 · 2014: 15 · 2013: 9 · 2012: 10
FWCI
23.77
Type
journal article
Language
en
Open access
closed
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
Keywords
ursodeoxycholic acid, primary biliary cirrhosis, long-term treatment, disease progression, liver transplantation, hyperbilirubinemia, variceal bleeding, ascites, encephalopathy, prognostic factors, bile acid therapy
MeSH terms
Double-Blind Method, Female, Humans, Liver Cirrhosis, Biliary, Male, Middle Aged, Regression Analysis, Risk Factors, Ursodeoxycholic Acid, Liver Transplantation, Treatment Outcome, Liver Failure, Treatment Failure

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ursodiol for the Long-Term Treatment of Primary Biliary Cirrhosis. https://app.cochat.ai/papers/10.1056/nejm199405123301903
The paper
Poupon, R. E., Poupon, R., & Balkau, B. (1994). Ursodiol for the Long-Term Treatment of Primary Biliary Cirrhosis. New England Journal of Medicine. https://doi.org/10.1056/nejm199405123301903

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.